Cargando…
A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991264/ http://dx.doi.org/10.1186/2051-1426-1-S1-O24 |
| _version_ | 1782312404180271104 |
|---|---|
| author | Sasikumar, Pottayil Shrimali, Rajeev Adurthi, Sreenivas Ramachandra, Raghuveer Satyam, Leena Dhudashiya, Amit Samiulla, Dodheri Sunilkumar, K B Ramachandra, Murali |
| author_facet | Sasikumar, Pottayil Shrimali, Rajeev Adurthi, Sreenivas Ramachandra, Raghuveer Satyam, Leena Dhudashiya, Amit Samiulla, Dodheri Sunilkumar, K B Ramachandra, Murali |
| author_sort | Sasikumar, Pottayil |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-3991264 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-39912642014-05-05 A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events Sasikumar, Pottayil Shrimali, Rajeev Adurthi, Sreenivas Ramachandra, Raghuveer Satyam, Leena Dhudashiya, Amit Samiulla, Dodheri Sunilkumar, K B Ramachandra, Murali J Immunother Cancer Oral Presentation BioMed Central 2013-11-07 /pmc/articles/PMC3991264/ http://dx.doi.org/10.1186/2051-1426-1-S1-O24 Text en Copyright © 2013 Sasikumar et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Oral Presentation Sasikumar, Pottayil Shrimali, Rajeev Adurthi, Sreenivas Ramachandra, Raghuveer Satyam, Leena Dhudashiya, Amit Samiulla, Dodheri Sunilkumar, K B Ramachandra, Murali A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events |
| title | A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events |
| title_full | A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events |
| title_fullStr | A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events |
| title_full_unstemmed | A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events |
| title_short | A novel peptide therapeutic targeting PD1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events |
| title_sort | novel peptide therapeutic targeting pd1 immune checkpoint with equipotent antagonism of both ligands and a potential for better management of immune-related adverse events |
| topic | Oral Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991264/ http://dx.doi.org/10.1186/2051-1426-1-S1-O24 |
| work_keys_str_mv | AT sasikumarpottayil anovelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT shrimalirajeev anovelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT adurthisreenivas anovelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT ramachandraraghuveer anovelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT satyamleena anovelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT dhudashiyaamit anovelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT samiulladodheri anovelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT sunilkumarkb anovelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT ramachandramurali anovelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT sasikumarpottayil novelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT shrimalirajeev novelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT adurthisreenivas novelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT ramachandraraghuveer novelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT satyamleena novelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT dhudashiyaamit novelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT samiulladodheri novelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT sunilkumarkb novelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents AT ramachandramurali novelpeptidetherapeutictargetingpd1immunecheckpointwithequipotentantagonismofbothligandsandapotentialforbettermanagementofimmunerelatedadverseevents |